Tokyo, August 31, 2020 — Corundum Systems Biology Inc., a Japan-based company dedicated to facilitating microbiome research and business creation, announces the CSB-1 (Luxembourg) SCSp (“CSB-1(LUX) SCSp”)Fund will invest in Seventure Partners’ Health for life Capital Il™ (HFL II) Fund. Corundum Systems Biology and Seventure Partners will also become strategic partners for Japan, paving way for enhanced access to information in microbiome innovation and potential.
Seventure Partners, based in France and acknowledged as a world leader in financing innovation, first launched in March 2014 the groundbreaking HFL I, a fund focused on the microbiome and health and nutrition sectors. The successor fund, HFL II was launched in Q1 2019. To date, HFL II has attracted strategic investments from active food, nutrition and healthcare players including Danone, Novartis, Lesaffre, Unigrains and Bel as well as many institutional financial investors. The HFL II fund target of €200 million (approximately JPY24 billion) has already been oversubscribed and the fund now targets €250-300 million for the final close which is expected end of 2020.
Through the strategic partnership with Seventure, Corundum Systems Biology will help expand business investment opportunities in Japan and Asia for HFL and HFLII microbiome portfolio companies.
Corundum Systems Biology Inc., established in Japan on April 30, 2020, has three key business focus:
- Develop biometric database and data analysis platform related to microbiome
- Develop new businesses in the field of microbiome
- Support facilitation and hastening of R&D related to microbiome
The CSB-1(LUX) SCSp Fund, with €20 million (approximately JPY2.4 billion) commitments under management, was established in Luxembourg in July 2020.
Public Relations, Corundum Systems Biology Inc.